Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.34 |
| ▸ | CASP3 | P42574 | 3/20 | 0.33 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20764509 | 1.00 | MDM4 (0.35) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL20764453 | 0.90 | CASP1 (0.34) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL20764454 | 0.90 | CASP1 (0.34) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL28376086 | 0.86 | CASP1 (0.33) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL20764469 | 0.85 | MDM4 (0.43) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL20764467 | 0.85 | MDM4 (0.43) | MDM4TP53MDM2CASP3TLR2 | |
| SCHEMBL20764450 | 0.79 | CASP3 (0.35) | MDM4TP53CASP3TLR2 | |
| SCHEMBL22284883 | 0.77 | MDM4 (0.42) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL17531773 | 0.77 | MDM4 (0.42) | MDM4TP53MDM2PTPN1CASP3 | |
| SCHEMBL19375786 | 0.77 | MDM4 (0.43) | MDM4TP53MDM2PTPN1CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | HELMHOLTZ-ZENTRUM FÜR (DE) | 2021-06-15 | — | — | US | disclosed |
| EP-3672937-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-07-01 | — | — | EP | disclosed |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2020-06-18 | — | — | US | disclosed |
| WO-2019038405-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | Helmholtz-Zentrum für Infektionsforschung GmbH (DE) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034648-B2 | Cystobactamide derivatives | CTH, CBS, SLC7A11 | MDM4 4343/4885TP53 3744/4885MDM2 3997/4885 |
| US-20200190020-A1 | NOVEL CYSTOBACTAMIDE DERIVATIVES | CTH, CBS, SLC7A11 | MDM4 4515/4885TP53 4050/4885MDM2 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.